Metformin rarely causes skin problems on its own. Despite being one of the most widely prescribed medications in the world, reports of metformin directly triggering skin reactions are scattered across a handful of case reports spanning decades. That said, the relationship between metformin and your skin is more layered than a simple yes or no. There are rare direct reactions, indirect effects through nutrient depletion, and, perhaps surprisingly, a growing body of evidence that metformin can actually improve certain skin conditions.
Direct Skin Reactions Are Rare but Real
Metformin has been in clinical use since the 1950s, and in that time, documented cases of the drug directly causing skin eruptions are strikingly few. One review noted that in the entire medical literature, only psoriasiform eruptions and leukocytoclastic vasculitis had been reliably attributed to metformin alone.
Leukocytoclastic vasculitis is an inflammation of small blood vessels that produces painful, purplish spots on the skin, usually on the lower legs. In one published case, a 33-year-old woman developed these lesions after starting metformin for weight loss. Her doctors suspected the drug, stopped it, and the rash cleared. A month later, she took metformin again, the same lesions came back, and a skin biopsy confirmed vasculitis. That rechallenge pattern is the strongest kind of evidence linking a drug to a reaction.1PubMed. Rare case of metformin-induced leukocytoclastic vasculitis
Fixed-drug eruptions are another rare but documented reaction. In one case, a woman developed small, round, reddish lesions on her palms and soles about two months after starting metformin. She described them as spots that would blister and then flake away, with the skin around them sometimes becoming painful. The eruptions recurred each time metformin was reintroduced, confirming the drug as the trigger.2PubMed Central. Metformin-Induced Fixed-Drug Eruption Confirmed by Multiple Exposures
Purpuric skin lesions, which look like flat purple or red spots that don’t fade when pressed, have also been reported. A 59-year-old woman newly started on metformin developed these on her arms, legs, and back within days. Switching her to a different diabetes medication resolved the problem.3International Journal of Basic & Clinical Pharmacology. Hypersensitivity reaction with metformin: a case report
To put these cases in perspective: a pharmacovigilance study analyzing over 10.5 million adverse event reports submitted to the FDA between 2004 and 2022 identified roughly 56,700 reports mentioning metformin. Among the flagged signals were skin eruption and pemphigoid, a blistering skin disease. But those signals have to be read carefully. The database captures what people and clinicians report, not necessarily what the drug caused. Metformin is used alongside many other medications, and teasing apart which drug is responsible for a skin reaction can be difficult.4PubMed. Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022
When the Problem Is the Combination, Not Metformin Alone
A common source of confusion is that metformin is frequently prescribed alongside other diabetes drugs, and the combination medication can cause skin reactions that get attributed to metformin. This has been well documented with DPP-4 inhibitors, a class of diabetes drugs sometimes combined with metformin in a single pill.
In one series, five out of six newly diagnosed bullous pemphigoid patients in a single dermatology department turned out to be taking a DPP-4 inhibitor combined with metformin. Bullous pemphigoid causes large, fluid-filled blisters, and it can be alarming. But when clinicians investigated, the blistering began only after the DPP-4 inhibitor was added, not when metformin was being used alone. Stopping the combination medication controlled the condition in all five patients.5PubMed. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin
The same pattern emerged in a case of generalized skin eruption where the patient had been on metformin for an extended period without issues. The rash appeared only after sitagliptin, a DPP-4 inhibitor, was added to the regimen.6SpringerLink. Drug-Induced Generalized Skin Eruption in a Diabetes Mellitus Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor Plus Metformin – Section: Discussion
If you develop a skin reaction while taking a metformin combination pill, the practical takeaway is that your doctor will likely want to figure out which ingredient is responsible before assuming metformin is the culprit. Often, switching to metformin alone or to a different combination resolves the issue.
The Vitamin B12 Connection to Skin Changes
One of metformin’s well-established side effects is reducing how well your body absorbs vitamin B12. This happens gradually, and many people taking metformin for years develop lower B12 levels without realizing it. The skin consequences of this deficiency can be puzzling because they don’t look like a typical drug reaction.
B12 deficiency can cause darkening of the skin, especially in the creases of the palms, between the fingers, on the soles of the feet, and in skin folds like the armpits and groin. The discoloration may also appear on the lips and as dark vertical streaks on the fingernails. This happens because low B12 ramps up the activity of an enzyme involved in producing melanin, the pigment that gives skin its color.7PubMed Central. Reversible Hyperpigmentation in a Patient With Vitamin B12 Deficiency – Section: Discussion
In one reported case, a 59-year-old woman on metformin developed dark spots that started on her palms and soles before spreading more widely across her body, with particular darkening in skin-fold areas and melanonychia on her nails.8Actas Dermo-Sifiliográficas. Vitamin B12 Deficiency and its Numerous Skin Manifestations Beyond hyperpigmentation, B12 deficiency can also cause glossitis (a smooth, sore tongue), cracking at the corners of the mouth, and hair changes.
The good news is that these skin changes are typically reversible once B12 levels are corrected with supplements. If you’ve been on metformin for more than a year or two and notice unusual darkening of your skin or changes to your nails, it’s worth asking your doctor to check your B12 level. Many clinicians now routinely monitor B12 in long-term metformin users, but it’s not universal practice.
When Metformin Helps Skin Rather Than Harms It
This is where the story gets counterintuitive. While the cases above describe metformin occasionally causing skin issues, a growing body of research suggests metformin may actually improve several common skin conditions. The drug’s anti-inflammatory properties and effects on insulin and blood sugar extend well beyond diabetes management.
Acanthosis nigricans, the dark, velvety thickening of skin that often appears on the neck, armpits, and groin, is driven by insulin resistance. Because metformin directly addresses insulin resistance, it can help fade these patches over time. Treatment guidelines for acanthosis nigricans emphasize addressing the underlying metabolic condition, and metformin is one of the first-line tools for doing so.9PubMed Central. Current treatment options for acanthosis nigricans
Acne linked to polycystic ovary syndrome responds to metformin as well. In women with PCOS, excess insulin drives the ovaries to produce more androgens, which in turn ramp up oil production and fuel breakouts. A clinical study found that metformin significantly reduced acne severity in women with PCOS by lowering ovarian androgen output.10PubMed Central. Efficacy of Metformin in the Treatment of Acne in Women with Polycystic Ovarian Syndrome: A Newer Approach to Acne Therapy
Hidradenitis suppurativa, a painful condition involving recurring abscesses and scarring in areas where skin rubs together, has also shown improvement with metformin. Research found that metformin reduced insulin resistance and improved cardiovascular risk markers in these patients, and its anti-inflammatory effects appear to reprogram immune cell behavior in ways that calm the disease.11PubMed Central. Metformin Treatment of Hidradenitis Suppurativa: Effect on Metabolic Parameters, Inflammation, Cardiovascular Risk Biomarkers, and Immune Mediators12British Journal of Dermatology. Metformin has anti-inflammatory effects and induces immunometabolic reprogramming via multiple mechanisms in hidradenitis suppurativa
Metformin and Psoriasis
Psoriasis and metabolic syndrome frequently overlap, and researchers have been investigating whether metformin’s metabolic benefits translate into skin improvements for psoriasis patients. A scoping review found an excellent therapeutic response to metformin in psoriasis patients who also had metabolic conditions like diabetes or obesity, though there was no clear evidence supporting metformin on its own in people without those comorbidities.13PubMed Central. Is Metformin a Possible Beneficial Treatment for Psoriasis? A Scoping Review – Section: 3.2. Evidence from Clinical Studies Supporting Add-On Metformin for Psoriasis
A meta-analysis looking at this question more rigorously found that metformin was associated with substantially better psoriasis outcomes when added to standard treatment. Patients taking metformin were far more likely to achieve meaningful reductions in their psoriasis severity scores, and their blood sugar, triglycerides, cholesterol, and LDL levels all improved as well.14PubMed Central. The efficacy of metformin for the treatment of psoriasis: a meta-analysis study The evidence is strongest for people with both psoriasis and metabolic problems, which is a sizable portion of psoriasis patients. Whether metformin would help psoriasis in someone who is otherwise metabolically healthy remains an open question.
Topical Metformin for Melasma
Some of the most intriguing recent research involves applying metformin directly to the skin rather than taking it orally. Melasma, the condition that causes brown or grayish patches on the face (especially common in women during pregnancy or with hormonal changes), has been a particular target.
A systematic review and meta-analysis found that 15% topical metformin significantly reduced melasma severity compared to placebo after eight weeks. At higher concentrations, 30% topical metformin performed comparably to triple combination cream, the current gold standard for melasma, while causing fewer side effects.15PubMed Central. Efficacy and safety of metformin for melasma treatment: a systematic review and meta-analysis An earlier clinical trial had reached a similar conclusion, describing topical metformin as a safe and nearly as effective alternative.16PubMed. Topical metformin in the treatment of melasma: A preliminary clinical trial
This is still early-stage research with small trials, so topical metformin for melasma isn’t standard practice yet. But it illustrates how the same drug that, in rare cases, triggers a skin reaction through one mechanism can also protect and heal skin through entirely different pathways.
Wound Healing and Skin Aging
Metformin’s effects on wound healing have attracted attention, particularly in the context of diabetes, where slow-healing wounds are a significant complication. Lab and animal research has shown that metformin accelerates wound closure through several routes: it shifts immune cells toward an anti-inflammatory state, improves blood vessel formation in healing tissue, and dials down the inflammatory signaling that stalls repair.17PubMed Central. Metformin induces the M2 macrophage polarization to accelerate the wound healing via regulating AMPK/mTOR/NLRP3 inflammasome singling pathway In diabetic animal models, metformin treatment enhanced wound healing by promoting cellular cleanup processes and managing the response to low-oxygen conditions that characterize chronic wounds.18PubMed. Metformin as a Modulator of Autophagy and Hypoxia Responses in the Enhancement of Wound Healing in Diabetic Rats
When applied directly to wounds in animal studies, metformin improved blood vessel formation in the healing area. The effect was tied to the same metabolic pathway that makes metformin effective for blood sugar control.19PubMed Central. Anti-aging pharmacology in cutaneous wound healing: effects of metformin, resveratrol, and rapamycin by local application
The aging skin angle is newer and largely based on cell culture and animal work, not human trials. Research on aging fibroblasts, the cells that produce collagen and maintain skin structure, found that metformin improved their ability to migrate and close wounds while normalizing age-related protein changes.20PubMed. Metformin promotes wound healing in senescent fibroblasts by regulating SIRT1 and FAP-α Separate lab work showed metformin could boost antioxidant capacity in aging skin cells, increase collagen production, and reduce the activity of enzymes that break down collagen.21Biomed Pharmacology J. Effect of Metformin on Interleukin-6 Expression in Human Fibroblast Cell Aging Model These findings help explain why metformin has become a molecule of interest in anti-aging research, though translating lab results to meaningful skin improvements in living, breathing humans still requires clinical trials.
Skin Cancer Risk
A separate and arguably more consequential line of research concerns metformin’s relationship with skin cancer. A propensity-matched case-control study found that metformin use was associated with a reduced risk of non-melanoma skin cancer, including both squamous cell carcinoma and basal cell carcinoma. The protective association held across different sex and ethnicity subgroups.22PubMed. Metformin Use and Risk of Non-Melanoma Skin Cancer: A Propensity-Matched Case-Control Study
For melanoma, the picture is more mixed. Preclinical work has shown that metformin can inhibit tumor growth and strengthen immune responses against melanoma cells. Some observational studies have reported improved outcomes in melanoma patients taking metformin, but the findings haven’t been consistent across all studies.23Journal of Drugs in Dermatology. The Emerging Role of Metformin in Skin Cancer: Mechanistic and Clinical Insights These are observational findings, meaning they can show associations but can’t prove that metformin itself is responsible for the reduced risk. People taking metformin may differ from non-users in ways that independently affect cancer risk. Randomized trials would be needed to settle the question, and those are underway or being planned for several cancer types.
What to Do If You Suspect a Skin Reaction
If you develop an unusual rash, blistering, dark patches, or purplish spots after starting metformin or a metformin-containing medication, the first thing to recognize is that other medications in your regimen are statistically more likely to be the cause. That said, metformin should still be on the differential list. Here are the practical steps worth knowing:
- Check the timing: Metformin-related skin reactions in the published cases appeared anywhere from days to about two months after starting the drug. If you’ve been on stable metformin for years with no issues, a new rash is more likely due to something else.
- Consider combination pills: If you’re taking a combination tablet that includes both metformin and another diabetes drug, the other ingredient may be the trigger. Your doctor can trial metformin alone to distinguish the two.
- Ask about B12: If the skin change involves darkening rather than a rash or blisters, B12 deficiency is a plausible culprit after long-term metformin use. A simple blood test can check this.
- Don’t stop abruptly on your own: Metformin is managing your blood sugar. Stopping it suddenly without medical guidance can lead to blood sugar spikes that carry their own risks. Work with your prescriber to figure out the cause and, if needed, switch medications safely.
The rechallenge pattern seen in published cases, where symptoms return after restarting the drug, is the most reliable way clinicians confirm a drug-skin connection. Your doctor may suggest this approach in a supervised setting if the reaction was mild and the diagnosis is uncertain.